Skandinaviska Enskilda Banken Ab (Publ) Acadia Pharmaceuticals Inc Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$16.32 - $20.92 $48,241 - $61,839	-2,956 Reduced 4.66%	60,514 $1.14 Million
Q4 2022 Feb 08, 2023	SELL	$14.2 - $18.63 $52,213 - $68,502	-3,677 Reduced 5.48%	63,470 $1.01 Million
Q1 2022 May 11, 2022	BUY	$20.94 - $27.5 $412,308 - $541,475	19,690 Added 41.49%	67,147 $1.63 Million
Q4 2021 Feb 10, 2022	SELL	$16.79 - $27.09 $727,007 - $1.17 Million	-43,300 Reduced 47.71%	47,457 $1.12 Million
Q3 2021 Nov 10, 2021	SELL	$15.78 - $24.77 $1.07 Million - $1.67 Million	-67,600 Reduced 42.69%	90,757 $1.51 Million
Q2 2021 Aug 10, 2021	BUY	$19.4 - $27.42 $2.36 Million - $3.34 Million	121,835 Added 333.59%	158,357 $3.86 Million
Q1 2021 May 14, 2021	BUY	$25.02 - $54.99 $913,780 - $2.01 Million	36,522 New	36,522 $942,000
Q3 2020 Nov 12, 2020	SELL	$36.42 - $57.0 $713,832 - $1.12 Million	-19,600 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$39.26 - $52.73 $769,496 - $1.03 Million	19,600 New	19,600 $950,000

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.